OLR1 and cardiovascular disorder: Considering all the data, targeting LOX-1 through different modulators such as monoclonal antibodies, the use of statins and by microRNAs has become an interesting strategy in tackling atherosclerosis, cardiovascular diseases and osteoarthritis (Hein et al, 2014; Luo et al, 2016; Hofmann et al, 2018).